Home > Back to Publisher > Report Information

The 2011-2016 World Outlook for In-Vitro Diagnostic Culture Media

Icon Group International, Inc.
January 20, 2011
186 Pages - SKU: ICN6298342

Abstract Table of Contents Related Reports

Countries covered: Global

This econometric study covers the world outlook for in-vitro diagnostic culture media across more than 200 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all of the 230 countries of the world). This study gives, however, my estimates for the worldwide latent demand, or the P.I.E., for in-vitro diagnostic culture media. It also shows how the P.I.E. is divided across the world’s regional and national markets. For each country, I also show my estimates of how the P.I.E. grows over time (positive or negative growth). In order to make these estimates, a multi-stage methodology was employed that is often taught in courses on international strategic planning at graduate schools of business.

1 INTRODUCTION: 1.1 Overview; 1.2 What is Latent Demand and the P.I.E.?; 1.3 The Methodology
2 SUMMARY OF FINDINGS: 2.1 The Worldwide Market Potential
3 AFRICA: 3.1 Executive Summary; 3.2 Algeria; 3.3 Angola; 3.4 Benin; 3.5 Botswana; 3.6 Burkina Faso; 3.7 Burundi; 3.8 Cameroon; 3.9 Cape Verde; 3.10 Central African Republic; 3.11 Chad; 3.12 Comoros; 3.13 Congo (formerly Zaire); 3.14 Cote d'Ivoire; 3.15 Djibouti; 3.16 Egypt; 3.17 Equatorial Guinea; 3.18 Ethiopia; 3.19 Gabon; 3.20 Ghana; 3.21 Guinea; 3.22 Guinea-Bissau; 3.23 Kenya; 3.24 Lesotho; 3.25 Liberia; 3.26 Libya; 3.27 Madagascar; 3.28 Malawi; 3.29 Mali; 3.30 Mauritania; 3.31 Mauritius; 3.32 Morocco; 3.33 Mozambique; 3.34 Namibia; 3.35 Niger; 3.36 Nigeria; 3.37 Republic of Congo; 3.38 Reunion; 3.39 Rwanda; 3.40 Sao Tome E Principe; 3.41 Senegal; 3.42 Sierra Leone; 3.43 Somalia; 3.44 South Africa; 3.45 Sudan; 3.46 Swaziland; 3.47 Tanzania; 3.48 The Gambia; 3.49 Togo; 3.50 Tunisia; 3.51 Uganda; 3.52 Western Sahara; 3.53 Zambia; 3.54 Zimbabwe
4 ASIA & THE MIDDLE EAST: 4.1 Executive Summary; 4.2 Afghanistan; 4.3 Armenia; 4.4 Azerbaijan; 4.5 Bahrain; 4.6 Bangladesh; 4.7 Bhutan; 4.8 Brunei; 4.9 Burma; 4.10 Cambodia; 4.11 China; 4.12 Hong Kong; 4.13 India; 4.14 Indonesia; 4.15 Iran; 4.16 Iraq; 4.17 Israel; 4.18 Japan; 4.19 Jordan; 4.20 Kuwait; 4.21 Kyrgyzstan; 4.22 Laos; 4.23 Lebanon; 4.24 Macau; 4.25 Malaysia; 4.26 Maldives; 4.27 Mongolia; 4.28 Nepal; 4.29 North Korea; 4.30 Oman; 4.31 Pakistan; 4.32 Palestine; 4.33 Papua New Guinea; 4.34 Philippines; 4.35 Qatar; 4.36 Saudi Arabia; 4.37 Seychelles; 4.38 Singapore; 4.39 South Korea; 4.40 Sri Lanka; 4.41 Syrian Arab Republic; 4.42 Taiwan; 4.43 Tajikistan; 4.44 Thailand; 4.45 The United Arab Emirates; 4.46 Turkey; 4.47 Turkmenistan; 4.48 Uzbekistan; 4.49 Vietnam; 4.50 Yemen
5 EUROPE: 5.1 Executive Summary; 5.2 Albania; 5.3 Andorra; 5.4 Austria; 5.5 Belarus; 5.6 Belgium; 5.7 Bosnia and Herzegovina; 5.8 Bulgaria; 5.9 Croatia; 5.10 Cyprus; 5.11 Czech Republic; 5.12 Denmark; 5.13 Estonia; 5.14 Finland; 5.15 France; 5.16 Georgia; 5.17 Germany; 5.18 Greece; 5.19 Hungary; 5.20 Iceland; 5.21 Ireland; 5.22 Italy; 5.23 Kazakhstan; 5.24 Latvia; 5.25 Liechtenstein; 5.26 Lithuania; 5.27 Luxembourg; 5.28 Malta; 5.29 Moldova; 5.30 Monaco; 5.31 Norway; 5.32 Poland; 5.33 Portugal; 5.34 Romania; 5.35 Russia; 5.36 San Marino; 5.37 Slovakia; 5.38 Slovenia; 5.39 Spain; 5.40 Sweden; 5.41 Switzerland; 5.42 The Netherlands; 5.43 The United Kingdom; 5.44 Ukraine
6 LATIN AMERICA: 6.1 Executive Summary; 6.2 Argentina; 6.3 Belize; 6.4 Bolivia; 6.5 Brazil; 6.6 Chile; 6.7 Colombia; 6.8 Costa Rica; 6.9 Ecuador; 6.10 El Salvador; 6.11 French Guiana; 6.12 Guatemala; 6.13 Guyana; 6.14 Honduras; 6.15 Mexico; 6.16 Nicaragua; 6.17 Panama; 6.18 Paraguay; 6.19 Peru; 6.20 Suriname; 6.21 The Falkland Islands; 6.22 Uruguay; 6.23 Venezuela
7 NORTH AMERICA & THE CARIBBEAN: 7.1 Executive Summary; 7.2 Antigua and Barbuda; 7.3 Aruba; 7.4 Barbados; 7.5 Bermuda; 7.6 Canada; 7.7 Cuba; 7.8 Dominica; 7.9 Dominican Republic; 7.10 Greenland; 7.11 Grenada; 7.12 Guadeloupe; 7.13 Haiti; 7.14 Jamaica; 7.15 Martinique; 7.16 Puerto Rico; 7.17 St. Kitts and Nevis; 7.18 St. Lucia; 7.19 St. Vincent and the Grenadines; 7.20 The Bahamas; 7.21 The British Virgin Islands; 7.22 The Cayman Islands; 7.23 The Netherlands Antilles; 7.24 The U.S. Virgin Islands; 7.25 The United States; 7.26 Trinidad and Tobago
8 OCEANA: 8.1 Executive Summary; 8.2 American Samoa; 8.3 Australia; 8.4 Christmas Island; 8.5 Cook Islands; 8.6 Fiji; 8.7 French Polynesia; 8.8 Guam; 8.9 Kiribati; 8.10 Marshall Islands; 8.11 Micronesia Federation; 8.12 Nauru; 8.13 New Caledonia; 8.14 New Zealand; 8.15 Niue; 8.16 Norfolk Island; 8.17 Palau; 8.18 Solomon Islands; 8.19 The Northern Mariana Island; 8.20 Tokelau; 8.21 Tonga; 8.22 Tuvalu; 8.23 Vanuatu; 8.24 Wallis and Futuna; 8.25 Western Samoa
9 DISCLAIMERS, WARRANTEES, AND USER AGREEMENT PROVISIONS: 9.1 Disclaimers & Safe Harbor; 9.2 ICON Group International, Inc. User Agreement Provisions

More Global General In Vitro Diagnostics Reports

Immunochemistry Analyzers and Test Kits - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018 by GlobalData
Immunochemistry Analyzers and Test Kits - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018 Summary GlobalData’s new report, “Immunochemistry Analyzers and Test Kits - Global ...

2012 Global Yersinia Diagnostics Market Outlook: Test Volume and Sales Forecasts by Country and Market Segment by Venture Planning Group
The report presents a detailed analysis of the Yersinia diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific ...

2012 Global Vibrio Diagnostics Market Outlook: Test Volume and Sales Forecasts by Country and Market Segment by Venture Planning Group
The report presents a detailed analysis of the Vibrio diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific ...

2012 Global Tuberculosis Diagnostics Market Outlook: Test Volumes, Sales Forecasts, and Supplier Shares by Country by Venture Planning Group
The report presents a detailed analysis of the Tuberculosis diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific ...

2012 Global Toxoplasmosis Diagnostics Market Outlook: Test Volumes, Sales Forecasts, and Supplier Shares by Country by Venture Planning Group
The report presents a detailed analysis of the Toxoplasmosis diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific ...

See all reports like this >>

The 2011-2016 World Outlook for In-Vitro Diagnostic Culture Media

Share this report

Other tasks

Research Assistance

Related Markets

General In Vitro Diagnostics Reports

Free Alert Me service